We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Automated Nucleated Red Blood Cell Enumeration Evaluated

By LabMedica International staff writers
Posted on 17 Jun 2015
The enumeration of nucleated red blood cell (NRBC) has been evaluated on a new automated hematology analyzer and to demonstrate the precision compared to manual counts (MC) at the various NRBC values.

The presence of peripheral blood nucleated red blood cell is associated with pathological conditions and leads to the overestimation of white blood cell count in automated hematology analyzers (HA) and therefore, accurate detection and enumeration of NRBCs are important.

Scientists at Mahidol University (Bangkok, Thailand) analyzed clinical blood specimens that were sent from both in- and out-patient departments to a central laboratory at during August 2013 and October 2013. More...
These peripheral blood specimens were collected using dipotassium ethylenediaminetetraacetic acid (EDTA) as an anticoagulant. The residual samples from routine testing with adequate volume for repeated testing were used and were analyzed within two hours of blood collection.

The automated hematology analyzer used was the Sysmex XN-3000 (Sysmex Corporation; Kobe, Japan) which comprises one sampler, two Sysmex XN Modular analyzers, and one Sysmex SP-10 slidemaker/stainer. Blood smears were prepared on the Sysmex SP-10 slidemaker/stainer using Wright-Giemsa reagent. Staff member counted the number of NRBCs per 200 white blood cells (WBCs) using light microscope at × 400 magnification. Included in the study were 234 specimens from 127 patients (54 males and 73 females) with initial reports of NRBCs more than 0.1% by automated hematology analyzer.

In the comparison study between XN and MC, NRBCs ranged from 0% to 612.5%. Regression analysis demonstrated a close accord between the methods. The mean bias of 14.1% with 95% limits of agreement between 48.76% and 76.95% was found. The NRBC counts from XN appeared to be more in accordance with MC when the NRBCs were lower than 200% with the concordance rate of 94.2%.

The authors concluded that the automated NRBC enumeration by XN was precise and could replace the traditional MC, especially for the specimens with NRBCs lower than 200%. This approach may improve laboratory management, especially for laboratories which frequently encounter normoblastemia. It should be noted that MC is a very laborious procedure requiring skilled technical knowledge. The study was published in the June 2015 issue of the International Journal of Laboratory Hematology.

Related Links:

Mahidol University 
Sysmex Corporation 



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.